{"issuance_frequency":"","notes_translated":{"fr":"L'article C.01.018 du titre 1 du Règlement sur les aliments et drogues exige du détenteur d'une autorisation de mise sur le marché (DAMM) qu'il analyse les données sur les effets indésirables du médicament et prépare un rapport de synthèse annuel. Les rapports de synthèse annuels doivent être fournis sur demande à Santé Canada. En outre, le paragraphe C.01.018(4) indique que le DAMM doit immédiatement prévenir Santé Canada en cas de changements importants concernant les risques et les avantages connus du produit de santé pendant la période visée par le rapport.","en":"Section C.01.018 of Division 1 of the Food and Drug Regulations requires the Market Authorization Holder (MAH) to analyze adverse drug reaction data and prepare an annual summary report. Annual summary reports are to be submitted when requested by Health Canada. In addition, Section C.01.018(4) requires that the MAH notify Health Canada without delay if there has been a significant change in what is known about the risks and benefits of the drug during the period covered by the report."},"issn":"","imso_approval":"true","isbn":"","creator":"","org_section":{"fr":"","en":""},"jurisdiction":"federal","private":false,"maintainer_email":"open-ouvert@tbs-sct.gc.ca","num_tags":0,"edition":"","frequency":"as_needed","data_series_issue_identification":{"fr":"","en":""},"contributor":{"fr":"","en":""},"maintainer":null,"ready_to_publish":"true","id":"ecf0de9f-e2b6-43aa-99b8-3f1c04b9beec","metadata_created":"2021-07-07T19:41:35.014953","subject":["health_and_safety"],"pspc_identification_number":"","metadata_modified":"2021-07-07T19:41:35.014959","author":null,"author_email":null,"geographic_region":[],"portal_release_date":"2021-07-07","digital_object_identifier":"","state":"active","version":null,"keywords":{"fr":["Avis","adoption de l'International Conference on Harmonisation","ICH","guidance on Periodic Benefit Risk Evaluation Report","ICH Topic E2C(R2)","titulaire de l'autorisation de mise sur le marché","données sur les effets indésirables des médicaments","rapport de synthèse annuel sur les effets indésirables des médicaments"],"en":["Notice","adoption of the International Conference on Harmonisation","ICH","guidance on Periodic Benefit Risk Evaluation Report","ICH Topic E2C(R2)","market authorization holder","adverse drug reaction data","adverse drug reaction annual summary report"]},"relationships_as_object":[],"creator_user_id":"2dc5a12f-2a6f-4822-8514-165ea6bb05d9","title_translated":{"fr":"Avis - L'adoption de la directive de l'International Conference on Harmonisation (ICH) intitulée: rapport périodique d'évaluation des avantages et des risques - ICH EC2 (R2), à partir du 1er mars 2013","en":"Notice - Adoption of the International Conference on Harmonisation (ICH) Guidance on Periodic Benefit Risk Evaluation Report - ICH Topic E2C(R2), as of March 1, 2013"},"type":"info","resources":[{"cache_last_updated":null,"unique_identifier":"","package_id":"ecf0de9f-e2b6-43aa-99b8-3f1c04b9beec","datastore_contains_all_records_of_source_file":false,"datastore_active":false,"character_set":"","related_type":"","state":"active","id":"c081b7a4-34ff-4daa-9349-09d59bf5e067","related_relationship":"","name_translated":{"fr":"Avis - L'adoption de la directive de l'International Conference on Harmonisation (ICH) intitulée: rapport périodique d'évaluation des avantages et des risques - ICH EC2 (R2), à partir du 1er mars 2013","en":"Notice - Adoption of the International Conference on Harmonisation (ICH) Guidance on Periodic Benefit Risk Evaluation Report - ICH Topic E2C(R2), as of March 1, 2013"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Notice - Adoption of the International Conference on Harmonisation (ICH) Guidance on Periodic Benefit Risk Evaluation Report - ICH Topic E2C(R2), as of March 1, 2013","language":["en"],"created":"2021-07-07T19:41:35.170896","url":"https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/international-conference-harmonisation/efficacy/notice-adoption-international-conference-harmonisation-guidance-periodic-benefit-risk-evaluation-report-topic-march-1-2013.html","last_modified":null,"position":0,"revision_id":"20f9ae93-b2bc-4082-b7a3-e011ad93fbdf","resource_type":"publication"},{"cache_last_updated":null,"unique_identifier":"","package_id":"ecf0de9f-e2b6-43aa-99b8-3f1c04b9beec","datastore_contains_all_records_of_source_file":false,"datastore_active":false,"character_set":"","related_type":"","state":"active","id":"6eb2d264-1676-4c6d-9bd1-af531b1e5e34","related_relationship":"","name_translated":{"fr":"Avis - L'adoption de la directive de l'International Conference on Harmonisation (ICH) intitulée: rapport périodique d'évaluation des avantages et des risques - ICH EC2 (R2), à partir du 1er mars 2013","en":"Notice - Adoption of the International Conference on Harmonisation (ICH) Guidance on Periodic Benefit Risk Evaluation Report - ICH Topic E2C(R2), as of March 1, 2013"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Notice - Adoption of the International Conference on Harmonisation (ICH) Guidance on Periodic Benefit Risk Evaluation Report - ICH Topic E2C(R2), as of March 1, 2013","language":["fr"],"created":"2021-07-07T19:41:35.170902","url":"https://www.canada.ca/fr/sante-canada/services/medicaments-produits-sante/medicaments/demandes-presentations/lignes-directrices/international-conference-harmonisation/efficacite/avis-adoption-directive-international-conference-harmonisation-intitulee-rapport-periodique-evaluation-avantages-risques-partir-1er-mars-2013.html","last_modified":null,"position":1,"revision_id":"20f9ae93-b2bc-4082-b7a3-e011ad93fbdf","resource_type":"publication"}],"place_of_publication":[],"num_resources":2,"tags":[],"spatial":"","collection":"publication","org_title_at_publication":{"fr":"Santé Canada","en":"Health Canada"},"date_published":"2013-04-10 00:00:00","issuance":"","groups":[],"license_id":"ca-ogl-lgo","data_series_name":{"fr":"","en":""},"relationships_as_subject":[],"license_title":"Open Government Licence - Canada","restrictions":"unrestricted","organization":{"description":"","created":"2016-09-23T17:25:33.001625","title":"Health Canada | Santé Canada","name":"hc-sc","is_organization":true,"state":"active","image_url":"","revision_id":"6a0471e8-36e5-4217-8f72-563c83e6465a","type":"organization","id":"BD26DB5E-82D2-42C1-99BB-08FCF6068FEE","approval_status":"approved"},"name":"ecf0de9f-e2b6-43aa-99b8-3f1c04b9beec","isopen":false,"additional_notes":{"fr":"","en":""},"departmental_identification_number":"","notes":"Section C.01.018 of Division 1 of the Food and Drug Regulations requires the Market Authorization Holder (MAH) to analyze adverse drug reaction data and prepare an annual summary report. Annual summary reports are to be submitted when requested by Health Canada. In addition, Section C.01.018(4) requires that the MAH notify Health Canada without delay if there has been a significant change in what is known about the risks and benefits of the drug during the period covered by the report.","owner_org":"BD26DB5E-82D2-42C1-99BB-08FCF6068FEE","program_page_url":{"fr":"","en":""},"url":null,"audience":[],"gc_catalogue_number":"","license_url":"http://open.canada.ca/en/open-government-licence-canada","series_publication_dates":{"fr":"","en":""},"title":"Notice - Adoption of the International Conference on Harmonisation (ICH) Guidance on Periodic Benefit Risk Evaluation Report - ICH Topic E2C(R2), as of March 1, 2013","revision_id":"20f9ae93-b2bc-4082-b7a3-e011ad93fbdf"}